

PRESS RELEASE

Ajinomoto Co., Inc.
15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JAPAN

Ajinomoto Co., Inc. to Sell* its Entire Equity Stake in Ajinomoto Althea, a US-based Aseptic Fill-Finish CDMO

Accelerating Value Enhancement in Biopharma Services within the Healthcare Area

*Completed on May 1, 2025

TOKYO, April 24, 2025 – Ajinomoto Co., Inc. (“Ajinomoto Co.”) announced today that it has signed a share transfer agreement (the “Agreement”) to sell all of its shares (the “Transaction”) of Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and a 100% subsidiary of Ajinomoto Co., to Packaging Coordinators Inc. (“PCI”).

Althea provides aseptic fill-finish services for clinical- and commercial-stage biopharmaceutical customers as a member of Ajinomoto Bio-Pharma Services. PCI is a leading global contract development and manufacturing organization (CDMO) providing clients with integrated end-to-end drug development, manufacturing, clinical trial services, advanced drug delivery and commercial packaging technology services, which has been actively investing to expand its sterile fill-finish capacity and capabilities, as exemplified by the acquisition of Lyophilization Services of New England, Inc. in 2021. Ajinomoto Co. has concluded that, given the strengths and service offering of both companies, PCI is the best partner for Althea to continue its growth and maximize its value to customers.

In accordance with the Medium-Term ASV Initiatives 2030 Roadmap announced in February 2023, Ajinomoto Co. is pursuing growth by focusing on the four strategic growth areas where high market growth potential as well as high social value are expected, leveraging the strengths of “AminoScience.” Within the Healthcare area, Ajinomoto Co. is focused on high value-added services driven by its proprietary technologies, and as part of this strategy, it has acquired Forge Biologics Holdings, entering into a gene therapy CDMO business. Ajinomoto Co. continues to operate CDMO business with focus mainly on further developing high value-added services where it can leverage its proprietary technologies and aims to accelerate growth and realize strong profitability in the Healthcare area.

The Transaction ~~is scheduled to be~~ was completed (*revised on May 9, 2025) in May 2025, subject to general preconditions stipulated in the Agreement. The impact of the Transaction on the Ajinomoto Co.’s financial results has been incorporated to the extent possible in the “[Notice of Revision to Consolidated Financial Results Forecasts and the Difference of Non-Consolidated Financial Results as Compared to Actual Results for the Previous Year]” announced today.

Reference

Overview of Althea

- (1) Company Name: Ajinomoto Althea, Inc.
- (2) Location: California, USA
- (3) Establishment: 1997
- (4) Representative: Brian Blagg (President & COO)
- (5) Number of Employees: approximately 500
- (6) Business Description: Drug product fill-finish and formulation services

- (7) Shareholder Composition: Ajinomoto Co. (100%)
- (8) Website: <https://www.ajibio-pharma.com/>

Overview of PCI

- (1) Company Name: Packaging Coordinators Inc.
- (2) Location: Pennsylvania, USA
- (3) Establishment: 2012
- (4) Representative: Salim Haffar (CEO)
- (5) Number of Employees: approximately 7,000
- (6) Business Description: Drug development, manufacturing, clinical trial services, advanced drug delivery services and commercial packaging technology services
- (7) Website: <https://pci.com/>

The Ajinomoto Group will contribute to the well-being of all human beings, our society and our planet with “AminoScience” based on the corporate slogan “Eat Well, Live Well.” The Ajinomoto Group has offices in 34 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2023, sales were 1.4392 trillion yen (9.9 billion U.S. dollars). To learn more, visit www.ajinomoto.com.

For further information, please contact: [HERE](#)